Transcept resubmits sleep drug NDA; Quintiles lays off workers;

 @FierceBiotech: Big Biotech joins Big Pharma in hunt for biosimilars. News | Follow @FierceBiotech

 @JohnCFierce: The view from the JP Morgan: Plenty of (hard) work available in 2011. Article | Follow @JohnCFierce 

> Transcept Pharmaceuticals ($TSPT) has resubmitted its NDA seeking approval of the long delayed sleep drug Intermezzo. Regulators denied approval in the fall of 2009, saying they wanted to see more data the drug would have on people who took it in the middle of the night. Under the licensing terms it struck with Purdue, any delay past the middle of 2010 carved $2 million a month out of a $30 million milestone. Transcept release

> The CRO Quintiles laid off some workers last week, but declined to say how many employees were affected by the move. Story

> Switzerland's Diagnoplex SA, a developer of molecular diagnostics for colon cancer, has closed a Series A financing extension with Debiopharm Group. Diagnoplex release

> Bayer says it plans to launch a Phase III program for a new treatment for severe myopia in several Asian countries. News

> Canadian regulators say they'll need to see more information on Osiris' Prochymal before they can approve it for graft vs. host disease. News

> After speaking with regulators in the U.S. and Europe, Pluristem says that it's ready to launch new studies of its placenta-derived cell therapy for blocked arteries. Article

And Finally... Japanese researchers are taking on big task, with plans to clone a mammoth using frozen tissue and an elephant surrogate mother. Report